Metformin

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Kidney, European Commission, Diabetes, INN, Risk, Allergy, ATC, Hypoglycemia, Hormone, International, Diet, Pancreas, European, Insulin, Metformin, Disease, Blood, Language, Glycated hemoglobin, DPP-4, Glucose, Type, Tablet, Select, Committee, Patient, Safety, Pioglitazone, Anatomy, Medicine, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Retrieved on: 
Monday, December 18, 2023
Patient, Immunotherapy, NGS, Neoplasm, PR, CDKN2B, CDK2, Histology, Glioma, DLT, CYCC, Lung, CDK9, PLK1, Metformin, Half-life, Melanoma, Hyperglycemia, Blood, Cyclacel, Cancer, Endometrial cancer, T-cell lymphoma, Mesothelioma, Head, Laboratory, Pancreatic cancer, MTAP, Biomarker, Tablet, Lymphoma, NSCLC, Deletion, PRMT5, Neck

BERKELEY HEIGHTS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.

Key Points: 
  • “The data suggest tumor sensitivity in patients with one or more of three abnormalities, CDKN2A, CDKN2B and/or MTAP deletion subject to confirmation in further studies.
  • The Phase 2 part of 065-101 is designed to evaluate fadra safety and efficacy in cohorts defined by histology and/or next generation sequencing (NGS).
  • “After retrospectively analyzing a subset of previously treated Phase 1 patients who experienced clinical benefit with fadra, we found four patients with CDKN2A, CDKN2B and/or MTAP deletions.
  • CDKN2B deletions occur in over 30% of several solid tumors, including bladder, glioma, pancreatic, esophageal, lung (incl.

Low-cost Interventions Could Ease the Burden of Diabetes, according to the Journal of American Physicians and Surgeons

Retrieved on: 
Wednesday, December 13, 2023
Liver, AAPS, Risk, Resveratrol, Physician, City, Glycemic index, Weight loss, Low-fat diet, Probiotic, Magnesium, Insulin, Diabetes, Metformin, Fasting, Berberine, Melatonin, Insulin resistance, Patient, Lifestyle (social sciences), Journal

Management requires chronic medication use, with the expectation that this will be required life-long, creating a huge burden on medical systems.

Key Points: 
  • Management requires chronic medication use, with the expectation that this will be required life-long, creating a huge burden on medical systems.
  • Recently, however, novel low-cost noninvasive treatment approaches demonstrate promise for the long-term remission of T2DM symptoms, write Paul Marik , M.D., and colleagues in the winter issue of the Journal of American Physicians and Surgeons.
  • Abnormalities that contribute to T2DM include insulin resistance, impaired insulin secretion, increased glucose production in the liver, and other factors.
  • “The suggested protocols need further study, and funding is needed for holistic diabetes management in medical systems.”
    The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.

Hims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss

Retrieved on: 
Monday, December 4, 2023
Health, Telemedicine, Virtual Medicine, Fitness & Nutrition, General Health, Vitamins, Supplements, Pharmaceutical, Topiramate, Metformin, Hims & Hers Health, Sleep, Obesity, Depression, Research, NYSE, FACP, Naltrexone, Major trauma, Medication, Psychology, Gambling, Overweight, Patient, Multimedia, FAAP, Movement, FOMA, Motivation, Weight gain, Digital, Weight loss, MD, CDC, SVP, Heart Health Park, Vitamin B12, Birth control, Nursing, Dietary supplement, Behavior, Hers, Bupropion

View the full release here: https://www.businesswire.com/news/home/20231204073836/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231204073836/en/
    Weight Loss by Hims & Hers (Graphic: Business Wire)
    The science-backed Weight Loss by Hims & Hers program is developed with the expert insight of Dr. Primack and a team of clinical experts in obesity medicine, psychology and nutrition.
  • The program offers a well-rounded and more affordable approach to reducing weight by addressing the underlying factors that affect people’s weight – Nutrition, Behavior, Movement and Medical Treatment.
  • Weight Loss by Hims & Hers aims to address these issues by taking on the physical and psychological factors that contribute to weight gain and loss.
  • For more information on Hims & Hers’ weight loss program, please visit https://www.forhers.com/weight-loss and https://www.hims.com/c/wm/introduction .

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

Retrieved on: 
Friday, December 1, 2023
Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Vomiting, Safety, NYSE, PFE, FPG, Fasting, Incidence, Plasma, Liver, Metformin, Patient, Journal, Nature, American Medical Association, Extrapyramidal system, Obesity, Diarrhea, Nausea, Pfizer, Human, Inc., Pharmaceutical industry, Glycated hemoglobin

Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial ( NCT04707313 ) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial ( NCT04707313 ) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
  • The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.
  • Placebo-adjusted reductions in mean body weight ranged from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks.
  • In both populations, danuglipron demonstrated a safety and tolerability profile consistent with the mechanism of action.

RxGo.com Offers Free Money Saving Coupons on Commonly Prescribed Diabetes Medications in Time for National Diabetes Month

Retrieved on: 
Wednesday, November 22, 2023
Metformin, Insulin, Ageing, Insulin glargine, Insulin lispro, Food, Patient, Pharmacy, Heart, Prescription, Health, Judgement, Cancer, Bangladesh Technical Education Board, Pharmaceutical industry, Diabetes

DENVER, Nov. 22, 2023 /PRNewswire-PRWeb/ -- In November, communities nationwide unite for National Diabetes Month to raise awareness about diabetes. This year emphasizes proactive measures to prevent health complications associated with diabetes. Diabetes, characterized by elevated blood glucose levels, impacts around 37 million Americans, posing risks to the eyes, kidneys, nerves, and heart, and increasing the likelihood of certain cancers.

Key Points: 
  • November marks National Diabetes Month, where communities nationwide emphasize preventing diabetes-related health issues, including taking medications on time.
  • Freestyle Libre 3 is actually not a medication but a small discrete glucose monitor for people with diabetes.
  • RxGo.com encourages people with a prescription for this drug to access a Metformin coupon today and immediately begin saving money.
  • It is prescribed for adults with type 1 or type 2 diabetes and for children aged at least 6 years with type 1 diabetes.

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Retrieved on: 
Tuesday, November 21, 2023
CNS, DNA, Neoplasm, Metformin, PIK3CA, PI3K, Patient, KZIA, Radiation, Standard of care, MD, Diagnosis, DMG, Survival, ONC201, Female, DIPG, Society, DMG interpersonal, Pharmaceutical industry, Medical imaging

SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.

Key Points: 
  • SYDNEY, Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting.
  • "The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies," stated Dr. John Friend, CEO Kazia.
  • "We are highly encouraged with the preliminary overall survival data from the PNOC022 clinical study that we believe will provide an alternative to the current therapies considered as standard of care."
  • Key paxalisib highlights from the meeting:
    Specifically, the authors observed how ONC201 over activates the PI3K-AKT pathway, which is the target pathway for paxalisib
    Two patient case studies were discussed; each receiving the combination of paxalisib and ONC201 through compassionate access
    Six-year old female with DIPG who received the combination of paxalisib and ONC201 after upfront radiation therapy.

Sigrid Therapeutics Launches the Glucose Stabiliser in the U.S.

Retrieved on: 
Tuesday, November 14, 2023
Meal, Metformin, Carbohydrate, Research, Entrepreneurship, Therapy, Bloating, Metabolism, DSM-IV codes, Fats, Prescription, Type 2 diabetes, Type 2, Diabetes, Glycated hemoglobin, Enzyme, Weight loss, Dietary supplement, MIAMI, Sigrid

MIAMI, Nov. 14, 2023 /PRNewswire/ -- Sigrid Therapeutics has launched the Glucose Stabiliser, an over-the-counter blood sugar control supplement that also reduces caloric intake from fats and carbs. With about 1 in every 10 Americans facing a Type 2 diagnosis and the growing popularity of medications used for weight loss for the general population, Sigird's strategic launch into the U.S. market could not have come at a better time.

Key Points: 
  • MIAMI, Nov. 14, 2023 /PRNewswire/ -- Sigrid Therapeutics has launched the Glucose Stabiliser, an over-the-counter blood sugar control supplement that also reduces caloric intake from fats and carbs.
  • While prescribed diabetes medications come with a long list of side effects, the Glucose Stabiliser has none.
  • "The Glucose Stabiliser is representative of Sigrid's mission of empowering those looking to transform their metabolism for the better in an approachable manner," said Sana Alajmovic," CEO of Sigrid Therapeutics.
  • Pricing for the Glucose Stabiliser starts at $99 and can be purchased online at sigridstabiliser.com.

Pioneering Phase III Clinical Trial Investigates Multiple Potential Long-COVID Treatments

Retrieved on: 
Thursday, November 2, 2023
Technology, Other Health, Health, Pharmaceutical, Health Technology, Other Science, Other Technology, Research, Software, Science, Clinical Trials, EDC, Incidence, Electronic data capture, McMaster University, PLS, Digestion, Metformin, Infection, Inflammation, DSM-IV codes, Cell, Long COVID, COVID, Disease, Fluvoxamine, COVID-19, SSRI, EHR, Patient, Electronic health record, Fatigue, Pharmaceutical industry

The trial was designed by researchers at McMaster University in Hamilton, Canada, and is aimed at addressing the persisting challenges posed by Long-COVID.

Key Points: 
  • The trial was designed by researchers at McMaster University in Hamilton, Canada, and is aimed at addressing the persisting challenges posed by Long-COVID.
  • As a multi-center study beginning with 1,500 patients, the trial will rigorously assess the efficacy of multiple potential treatment options – beginning with fluvoxamine and metformin – in alleviating the symptoms associated with Long-COVID.
  • The trial will leverage state-of-the-art data management via an EDC developed by Yonalink, to ensure the highest caliber of data integrity.
  • The new approach seeks to swiftly identify effective Long-COVID-19 treatments and assess comparative efficacy without compromising the rigorous standards of a randomized clinical trial.

Porosome Therapeutics Announces Groundbreaking Approach to Advance Diabetes Treatment

Retrieved on: 
Monday, October 30, 2023
Biotechnology, Diabetes, Pharmaceutical, Health, Type 1 diabetes, Metformin, Jena, Cell, Protein, Disease, T2D, Cancer, Cystic fibrosis, Type 2 diabetes, Type 2, Proteome, T1D, Therapy, IPSC, Insulin, Pharmaceutical industry, Porosome

Porosome Therapeutics, Inc. (Porosome Therapeutics) has announced a new and distinctive therapy for Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) targeting the insulin secretory defects founds in beta cells associated with the disease.

Key Points: 
  • Porosome Therapeutics, Inc. (Porosome Therapeutics) has announced a new and distinctive therapy for Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) targeting the insulin secretory defects founds in beta cells associated with the disease.
  • Porosome Therapeutics’ approach addresses the cell's secretory machinery.
  • Porosome Therapeutics Founder and Chairman Professor Bhanu P. Jena discovered a new cellular structure called the porosome nearly three decades ago.
  • “These groundbreaking developments to treat diabetes directly address insulin secretion in cells and provide tremendous promise for people with diabetes,” said Guillermo Marmol, CEO, Porosome Therapeutics.